| Patient |
UM4033 |
MM0001 |
MM0002 |
UM5061 |
UM5043 |
MM0008 |
MM0007 |
MM0004 |
MM0005 |
| Time to Metastasis (Months) |
25 |
177 |
94 |
56 |
17 |
185 |
273 |
66 |
240 |
| Survival with Mets (Months) |
40 |
97 (a) |
51 (a) |
71 |
27 |
30 |
123 |
49 |
52(a) |
| Initial Metastasis Location |
Liver |
Liver |
Liver |
Liver |
Liver |
Lung |
Lung; Breast |
Liver |
Lung |
| Additional Met Locations |
None |
Skin; Peritoneum; Lung |
None |
Bone |
Lung |
None |
Liver; Bone |
Bone, adrenal |
None |
| Initial # Hepatic Mets |
3 |
3 |
1 |
1 |
>5 |
N/A |
N/A |
3 |
N/A |
| Systemic Chemo |
TMZ |
Taxol;Sorafenib+ Bevacizumab; Sunitinib; |
None |
TMZ; C/T;DTIC + Sorafenib; Sorafenib;CVD |
TMZ; CVD |
Imatinib |
Sunitinib |
C/T +/Sorafenib; Sorafenib |
Abraxane;ANA773 Tosylate;Sunitinib |
| Other Treatment |
IHP |
IHP/GM-CSF; SR; IL-2, PD-1 |
SR |
SR, IL-2 |
IL-2 |
StR |
SR, TGF- b |
SR |
SR |
| Initial Response to Treatment |
Stable Disease |
Disease Regression |
No Recurrence |
Disease Regression |
Disease Progression |
Stable Disease |
Disease Regression |
Stable Disease |
No Recurrence |
| LDH |
144 |
155 |
231 (high)*
|
N/A |
132 |
156 |
N/A |
201 (high) |
N/A |
| LFTs |
AST 21; |
AST 18; |
AST 34; |
AST 24; |
AST 21; |
N/A |
AST 24; |
AST 27; |
N/A |
|
ALT 24 |
ALT 18; |
ALT 33; |
ALT 18; |
ALT 26; |
N/A |
ALT 28; |
ALT 34; |
N/A |
|
AP 69 |
AP 44 |
AP 90 |
AP 72 |
AP 46 |
N/A |
AP 87 |
AP 98 |
N/A |
Liver function tests (LFTs) from time of first metastasis presentation: AST – Aspartate Transaminase (ref range: 5-34), ALT – Alanine Transaminase (8-35), AP – Alkaline
Phosphatase (38-126); LDH- lactate dehydrogenase (100-190U/L); Other Treatments: IHP – Isolated hepatic perfusion, SC – Systemic Chemotherapy, SR – Surgical Resection, StR
– Stereotactic radiotherapy; Biotherapies: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Interleukin 2 (IL-2), Programmed death 1 (PD-1) monoclonal antibody
vaccine, Transforming Growth Factor β (TGF-β), and ANA773 Tosylate (Toll-Like Receptor-7 Agonist); Systemic chemo regimens: Temozolomide (TMZ), Paclitaxel (Taxol),
Carboplatin + Paclitaxel (C/T), Cisplatin + Vinblastine + Dacarbazine (CVD), Dacarbazine (DTIC), Albumin-Bound Paclitaxel (Abraxane).
* LDH level was in normal range (178) one month later with no intervention.